Zobrazeno 1 - 10
of 466
pro vyhledávání: '"Gerard J, Nuovo"'
Autor:
Mohamed Omer, MD, MHA, MSc, Nicole Trepanowski, MD, Sara Yumeen, MD, Fatima N. Mirza, MD, MPH, Hayley S. Goldbach, MD, Deep Joshipura, MD, Sook-Bin Woo, DMD, Gerard J. Nuovo, MD, Leslie Robinson-Bostom, MD
Publikováno v:
JAAD Case Reports, Vol 42, Iss , Pp 52-55 (2023)
Externí odkaz:
https://doaj.org/article/8b10fb68e75a4fc2bf68213169360035
Autor:
Michela Garofalo, Young-Jun Jeon, Gerard J. Nuovo, Justin Middleton, Paola Secchiero, Pooja Joshi, Hansjuerg Alder, Natalya Nazaryan, Gianpiero Di Leva, Giulia Romano, Melissa Crawford, Patrick Nana-Sinkam, Carlo M. Croce
Publikováno v:
PLoS ONE, Vol 17, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/da59c71250ec495d913df7b1f0a30155
Autor:
Young-Jun Jeon, Taewan Kim, Dongju Park, Gerard J. Nuovo, Siyeon Rhee, Pooja Joshi, Bum-Kyu Lee, Johan Jeong, Sung-suk Suh, Jeff E. Grotzke, Sung-Hak Kim, Jieun Song, Hosung Sim, Yonghwan Kim, Yong Peng, Youngtae Jeong, Michela Garofalo, Nicola Zanesi, Jonghwan Kim, Guang Liang, Ichiro Nakano, Peter Cresswell, Patrick Nana-Sinkam, Ri Cui, Carlo M. Croce
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
TUSC3 resides on chromosome 8p which is frequently deleted in advanced stage tumors. Here, the authors show that TUSC3 loss mediated by miR-224/-520c promotes NSCLC metastasis where it enhances ATF-6α-dependent UPR and HRD-1 dependent ERAD, which in
Externí odkaz:
https://doaj.org/article/20aea16a00a84e518d6ba422033dbee0
Autor:
Marco Galasso, Carl Morrison, Linda Minotti, Fabio Corrà, Carlotta Zerbinati, Chiara Agnoletto, Federica Baldassari, Matteo Fassan, Armando Bartolazzi, Andrea Vecchione, Gerard J. Nuovo, Gianpiero Di Leva, Stefania D’Atri, Ester Alvino, Maurizio Previati, Brian J. Nickoloff, Carlo M. Croce, Stefano Volinia
Publikováno v:
Molecular Cancer, Vol 17, Iss 1, Pp 1-6 (2018)
Abstract Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211,
Externí odkaz:
https://doaj.org/article/276b897ea58a4f74b9ffb33c4fd15ed6
Autor:
Flavia Pichiorri, Craig C. Hofmeister, Balveen Kaur, Robert Baiocchi, John C. Byrd, Don M. Benson, Pearlly Yan, Alena Cristina Jaime-Ramirez, Matthew Old, Joseph Badway, Emily Smith, Alessandro Canella, Sarah Y. Schlotter, Xiaokui Mo, Gerard J. Nuovo, Douglas W. Sborov, Enrico Caserta, Andrew Stiff
Supplementary Fig. S1. Therapeutic efficacy of RV and HDACi against cancer B cells; Supplementary Fig. S2. HDACi increase JAM-1 expression without affecting cell viability; Supplementary Fig. S3. RV+HDACi display synergistic anti-myeloma activity; Su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::108dc400925926059cd6d97a1b4b5039
https://doi.org/10.1158/1535-7163.22508208.v1
https://doi.org/10.1158/1535-7163.22508208.v1
Autor:
Craig C. Hofmeister, Michael R. Grever, Flavia Pichiorri, Ashley E. Rosko, Yvonne A. Efebera, Don M. Benson, Gregory B. Lesinski, Thomas Mace, Andrew Stiff, Gerard J. Nuovo, Douglas W. Sborov
Supplementary table 1. Selected early phase clinical trials evaluating Reolysin single-agent and combination treatment regimens. Abbreviations: SD = stable disease, PR = partial response, CR = complete response; ER = endoplasmic reticulum.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161226b48b79994fd93c3addfbb88ff5
https://doi.org/10.1158/1078-0432.22455674
https://doi.org/10.1158/1078-0432.22455674
Autor:
Craig C. Hofmeister, Michael R. Grever, Flavia Pichiorri, Ashley E. Rosko, Yvonne A. Efebera, Don M. Benson, Gregory B. Lesinski, Thomas Mace, Andrew Stiff, Gerard J. Nuovo, Douglas W. Sborov
supplemental legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b0821ff343d97e4b10a5dcf43780667
https://doi.org/10.1158/1078-0432.22455668.v1
https://doi.org/10.1158/1078-0432.22455668.v1
Autor:
Craig C. Hofmeister, Michael R. Grever, Flavia Pichiorri, Ashley E. Rosko, Yvonne A. Efebera, Don M. Benson, Gregory B. Lesinski, Thomas Mace, Andrew Stiff, Gerard J. Nuovo, Douglas W. Sborov
Purpose: Reolysin, a proprietary isolate of reovirus type III dearing, enters and preferentially induces apoptosis of malignant cells. RAS pathway activation has been associated with more efficient reoviral infectivity and enhanced oncolysis. Reoviru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11979b1ca5f78b7ddf45f7285b2ba50e
https://doi.org/10.1158/1078-0432.c.6523079.v1
https://doi.org/10.1158/1078-0432.c.6523079.v1
Autor:
Craig C. Hofmeister, Michael R. Grever, Flavia Pichiorri, Ashley E. Rosko, Yvonne A. Efebera, Don M. Benson, Gregory B. Lesinski, Thomas Mace, Andrew Stiff, Gerard J. Nuovo, Douglas W. Sborov
Supplementary table 2. Five patients experienced at least grade 2 adverse events. Two of the 5 patients received at least 4 cycles of treatment, and the associated adverse events were noted after cycle 1. All cytopenias resolved prior to the completi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5714b4a5ecd572f8b5b82f9a130f50
https://doi.org/10.1158/1078-0432.22455671
https://doi.org/10.1158/1078-0432.22455671
Autor:
Craig C. Hofmeister, Michael R. Grever, Flavia Pichiorri, Ashley E. Rosko, Yvonne A. Efebera, Don M. Benson, Gregory B. Lesinski, Thomas Mace, Andrew Stiff, Gerard J. Nuovo, Douglas W. Sborov
Supplementary figure 1. The top ten worst adverse events include grade 1 - 3 events. Grade 1 events included decreased neutrophil, white blood cell, lymphocyte, and platelet counts, increased aspartate aminotransferase and alkaline phosphatase, and n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0378a076417be014eae17ea0afd79b4a
https://doi.org/10.1158/1078-0432.22455677.v1
https://doi.org/10.1158/1078-0432.22455677.v1